Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M

Financial framing remained anchored on the same runway and 2026 cash operating expense guidance, while Q1 2026 highlighted a "30% year-over-year reduction" in cash operating expenses and quarter-end ...
Fierce Biotech

After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Time-Preference Theory of Interest: Overview and History

The time preference theory of interest explains interest rates in terms of people's preference to spend in the present over ...
Scientific Research Publishing

Journalism in 280 Characters: Examining Dominant Issues and Communicative Functions in the X Posts of Mainstream Journalists in Ghana ()

Sackey, R. (2026) Journalism in 280 Characters: Examining Dominant Issues and Communicative Functions in the X Posts of Mainstream Journalists in Ghana. Open Journal of Social Sciences, 14, 516-557.
Forbes

The Most Important Idea In AI: Recursive Self Improvement

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Seeking Alpha

Recursion jumps as J.P. Morgan upgrades on lead program

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
STAT

Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
GEN

Recursion, Roche Unveil Microglia Map of Neuro Disease Targets

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
The Motley Fool

Is Recursion Pharmaceuticals a Millionaire Maker?

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Benzinga.com

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...